Onkológia 2/2025
Everolimus in treatment of HR-positive/HER2-negative breast cancer – clinical experience
HR-positive HER2-negative advanced/metastatic breast cancer is an incurable disease and eventually all patient will experience disease progression. Treatment is based on exploiting endocrine sensitivity of tumor cells. Majority of patients is also inicially treated with with CDK4/6 inhibitor. Upon progression, further endocrine treatment in combination with mTOR inhibitor everolimus is one of recommended treatment options.
Keywords: advanced breast cancer, mTOR inhibition, everolimus, HR-positive, HER2-negative